Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amid conflict concerns, industry wants bigger slice of $3bn Calif stem cell initiative

This article was originally published in Scrip

Executive Summary

The $3.0 billion state initiative in California promoting stem cell research has failed so far to stimulate commercial stem cell operations, companies and investors argued at a 10 April public hearing at the University of California, Irvine. Critics complained that too much of the money dispensed so far has gone to academic research groups, a pattern reinforced as early commercial development have hit hurdles. But some industry representatives predicted that companies would reap greater benefits from a subsequent phase of the initiative that focuses on translational work.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016957

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel